22 June 2020 SLAS Transformed is an interactive event focused on omics, synthetic biology and genome editing along with applicable implications for the current pandemic. The two-day event runs from 23-24 June 2020, offering 30-minute scientific research presentations, live exhibitor presentations and one-on-one networking sessions. It will span multiple… Read More
19 June 2020 CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June. Tumor-derived GDF-15 suppresses T-lymphocyte recruitment… Read More
19 June 2020 AFFiRiS has announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early PD patients were published in the peer-reviewed journal The Lancet Neurology. Results of the phase 1 clinical program with AFFiRiS’ lead candidate PD01 in early Parkinson’s… Read More
AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More
Avacta Group, in collaboration with the Centre for Virus Research at the University of Glasgow, has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein, prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection. Avacta… Read More
Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based… Read More
17 June 2020 Ubiquigent is continuing its collaboration with Bristol Myers Squibb. The collaboration, originally between Ubiquigent and Celgene, will allow Bristol Myers Squibb to capitalise on Ubiquigent’s deubiquitylase (DUB) enzyme inhibitor drug discovery platform. The central role of ubiquitylation in diverse cellular processes, including protein degradation, makes… Read More
17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More
New antibody internalization advanced screening method provides greater speed & insight 26 May 2020 Sponsored by Sartorius Researchers abilities to improve the breadth of therapeutic antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody… Read More
Collaborative Drug Discovery (CDD), owner of the CDD Vault, a comprehensive drug discovery informatics platform for research laboratories, has asked researchers what they think biotechnology world will look like after Covid-19. A few responses are listed below. “Covid-19 may be the tipping point that shifts us from the… Read More
The global biotech company announced the launch of its new cell-based vaccine platform targeting severe acute respiratory syndrome SARS-CoV-2, as well as other viral diseases such as Zika, West Nile Virus, Yellow Fever, Dengue Fever, MERS, HCV and Cytomegalovirus infection (CMV). Orgenesis said it has been “working aggressively”… Read More
13 May, 2020 The UK headquartered clinical development organisation, specialised in topical and transdermal drug delivery, has expanded its testing models to support pharmaceutical development programmes targeting coronavirus treatments. MedPharm said these models allow companies to assess therapeutic effectiveness in nasal, airway (bronchial) and deep lung (alveolar) epithelia… Read More
06 May, 2020 Spain based private biotechnology company Algenex announced that it is advancing the application of its CrisBio-based vaccine production technology in human health. Building on its expertise in the production of proteins for veterinary vaccines, Algenex said it has started to produce biotechnology products for the… Read More
The Israel based developer of nearly painless intradermal delivery solutions for vaccines and drugs said it is joining forces with leading vaccine and immunotherapy companies worldwide to share its proprietary MicronJet microneedle device. According to NanoPass, the aim is to enable the development of a safe, effective and… Read More
Oxford University and its spin-out company Vaccitech announced an agreement with UK based biopharmaceutical specialist AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate, currently being trialled by the University. With immediate effect, the partnership is said to allow for rapid vaccination… Read More
The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered… Read More